Education
About Us
Working with TipRanks
Follow Us
Statera BioPharma (STAB)
OTHER OTC:STAB
Total Valuation
Statera BioPharma has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Statera BioPharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Statera BioPharma’s return on equity (ROE) is 111.23 and return on invested capital (ROIC) is -1141.10%.
Return on Equity (ROE)111.23
Return on Assets (ROA)-8.24
Return on Invested Capital (ROIC)-1141.10%
Return on Capital Employed (ROCE)-9.91
Revenue Per Employee0.00
Profits Per Employee-2.21M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Statera BioPharma is ―. Statera BioPharma’s PEG ratio is -0.00054.
PE Ratio―
PS Ratio0.00
PB Ratio-51.50
Price to Fair Value-51.50
Price to FCF-2.85
Price to Operating Cash Flow>-0.01
PEG Ratio-0.00054
Income Statement
In the last 12 months, Statera BioPharma had revenue of 0.00 and earned -174.41M in profits. Earnings per share was -4.97.
Revenue0.00
Gross Profit-488.31K
Operating Income-98.34M
Pretax Income-101.88M
Net Income-174.41M
EBITDA-170.65M
Earnings Per Share (EPS)-4.97
Cash Flow
In the last 12 months, operating cash flow was -12.86M and capital expenditures -103.37K, giving a free cash flow of -12.96M billion.
Operating Cash Flow-12.86M
Free Cash Flow-12.96M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Statera BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Statera BioPharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Statera BioPharma as a current ratio of 0.37, with Debt / Equity ratio of -1037.04%
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.19
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Statera BioPharma has paid 72.53M in taxes.
Income Tax72.53M
Effective Tax Rate-0.71
Enterprise Valuation
Statera BioPharma EV to EBITDA ratio is 2.44, with an EV/FCF ratio of -3.35.
EV to Sales0.00
EV to EBITDA2.44
EV to Free Cash Flow-3.35
EV to Operating Cash Flow-3.38
Balance Sheet
Statera BioPharma has $506.10K in cash and marketable securities with $7.41M in debt, giving a net cash position of -$6.90M billion.
Cash & Marketable Securities$506.10K
Total Debt$7.41M
Net Cash-$6.90M
Net Cash Per Share-$10.00T>
Tangible Book Value Per Share-$0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Statera BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―